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Abstract
Background: Heart Failure (HF) is a low grade inflammatory condition. High sensitivity C-reactive protein (hsCRP) is
an established marker of inflammation. A cut-off value of hsCRP beyond which an infection should be sought has
never been studied in HF. We aimed to determine the best hsCRP cut-off for infection prediction in acute HF.
Methods: We analyzed patients included in an acute HF registry – EDIFICA (Estratificação de Doentes com
InsuFIciência Cardíaca Aguda). Admission hsCRP measurement was available as part of the registry’s protocol.
Patients with acute coronary syndrome as the cause of acute HF were excluded from the registry. Infection was
considered according to the diagnosis registered in the discharge record. A receiver-operating characteristic (ROC)
curve was used to determine the best hsCRP cut-off for infection prediction.
Results: We studied 615 patients. Mean age was 76 years, 45.2% were male, 60.3% had systolic dysfunction. Median
admission hsCRP was 20.3 (9.5–55.5)mg/L; in 41.6% the cause of decompensation was an infection. The area under
the ROC curve for admission hsCRP in the prediction of infection was 0.79 (0.76–0.83); the best hsCRP cut-off was
25 mg/L with a sensitivity of 72.7%, specificity 77.2%, positive predictive value 69.4% and negative predictive value
79.9%. Age and elevated hsCRP independently associated with an infection as the precipitant of acute HF.
Conclusions: We suggest 25 mg/L as a cut-off beyond which an infection should be sought underlying acute HF.
Almost 80% of the patients with hsCRP< 25 mg/L are not infected and 69.4% of those with higher hsCRP have a
concomitant infection.
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Background
Inflammation appears to play a central role in the patho-
physiology of heart failure (HF) [1, 2]. Several studies
have corroborated this inflammatory hypothesis, which
stands that endogenous cytokine cascades are implicated
in the development and progression of HF [1, 3–8].
Inflammatory biomarkers are elevated in the blood of
patients with HF [9, 10]. C-reactive protein is an acute-
phase protein mainly synthesized in the liver; it is the
most widely used and accepted marker to assess inflam-
mation in everyday clinical practice [9].
HF can be considered a low-grade inflammatory con-
dition. Chronic HF patients have increased levels of
high-sensitivity C-reactive protein (hsCRP), regardless of
the HF aetiology, and its levels increase with the severity
of the disease [4, 9, 11–14].There is also clear evidence
that a systemic inflammatory response is activated in
acute HF [10, 15, 16]. Most studies demonstrating this
inflammatory response in acute HF excluded patients
with infection or other inflammatory conditions in order
to prove the independent role of inflammation in HF
[10, 17]. Notwithstanding, infection is well known to
frequently underlie HF decompensation [18–20].
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For the general population and patients with stable
coronary artery disease, an also well established low-grade
inflammatory condition [8], the hsCRP cut-offs proposed
for future risk of cardiovascular events are < 1 mg/L (low
risk), 1-3 mg/L (intermediate risk) and > 3 mg/L (high
risk). Levels > 10 mg/l should be disregarded and repeated
after 2 weeks to allow any inflammation to resolve and if
repeated levels persist > 10 mg/L, a non cardiovascular
aetiology for such hsCRP elevation should be considered
[21, 22]. No hsCRP value beyond which an inflammatory
or infectious condition has to be excluded as ever been
proposed for HF, neither acute, nor chronic. The know-
ledge of such a cut-off would be particularly useful in the
acute setting in which an infection is often the precipitant
of HF decompensation.
The aim of our work was to determine the best cut-off
value of hsCRP to predict infection in patients present-
ing with acute HF.
Methods
We conducted a retrospective cohort study in a group of
patients that had been included in an acute HF registry -
EDIFICA (Estratificação de Doentes com InsuFIciência
Cardíaca Aguda) - that took place in the Internal Medi-
cine department of São João Hospital Center between
January 2009 and December 2010. Patients eligible for
inclusion were all patients admitted to our department
with the primary diagnosis of acute HF during such
period; both de novo and worsening chronic HF were
eligible. The 2008 European Society of Cardiology guide-
lines were used for the diagnosis of HF [20] and both
patients with reduced and preserved ejection fraction
were included; patients with ejection fraction≥50% were
considered to have HF with preserved ejection fraction
(HFpEF). Patients with acute coronary syndrome as the
cause of acute HF were excluded from the registry. A
complete physical examination at admission and in the
discharge day was performed to all patients. A 12-lead
electrocardiogram was also performed at admission. As
part of the registry’s protocol, patients were drawn a
venous blood sample within the first 48 h of hospital
admission. An echocardiogram was performed to all
patients during hospitalization, images were obtained
with a standard ultrasound equipment (System 6, GE
Vingmed, Horten, Norway) with a 2.5-MHz probe. The
patient’s treatment strategy, timing of discharge and
discharge medication were at the discretion of the
attending physician. The attending physicians were
aware of the ongoing registry.
B-type natriuretic peptide (BNP) determination is a routine
laboratory procedure in our hospital; an Abbott chemilumi-
nescentmicroparticle immunoassay (2-step immunoassay) is
used. Serum creatinine was measured using conventional
methods with an Olympus AU5400® automated clinical
chemistry analyzer Beckman-Coulter®. Haemoglobin was
obtained using an automated blood counter Sysmex® XE-
5000 (Hyogo, Japan), differential blood counts were also
performed in accordance with routine clinical practice.
Serum hsCRP was assayed using particle-enhanced
immunonephelometric assays on a BN™II laser nephel-
ometer (Siemens, Erlangen, Germany). The manufac-
turer claims, for three different hs-CRP concentrations,
2.39 mg/L, 6.50 mg/L, 7.72 mg/L, intra-assay coefficients
of variation (CV) of 5.2%, 5.0% and 4.6%, respectively,
and inter-assay CV of 5.2%, 5.7% and 5.4%. The normal
range of hsCRP is < 3.00 mg/L.
The glomerular filtration rate was estimated using the
Modification of Diet in Renal Disease (MDRD) Study
Equation.
All patients provided written informed consent to par-
ticipate in the study. The registry’s protocol conformed
to the ethical guidelines of the declaration of Helsinki
and it was approved by the local ethics committee.
A retrospective analysis was conducted in this patient co-
hort to determine the admission hsCRP beyond which an
infectious condition should be sought. Patients with missing
data regarding admission hsCRP (26 patients) were excluded
from the analysis. The study flow chart is depicted in Fig. 1.
An infectious condition at admission and underlying
acute HF was considered according to the discharge diag-
nosis list as judge by the attending physician and also
according to the information in the discharge record.
Statistical analysis
We used a receiver-operating characteristic (ROC) curve
to define the best hsCRP cut-off for association with an
infectious condition. The area under the ROC curve
(AUC) was determined.
Patients with an infectious condition underlying acute
HF and those without concomitant infection were com-
pared; and patients with hsCRP< 25 mg/L and those with
≥25 mg/L were also compared: Chi square test for cat-
egorical variables, Student’s t test to compare continuous
variables and a Mann-Whitney U test when continuous
variables had a highly skewed distribution. Variables inde-
pendently associated with infection upon admission and
underlying HF decompensation and variables independ-
ently associated with elevated hsCRP were assessed using
multivariate logistic regression analysis. Models were built
taking into consideration variables with a differential dis-
tribution between the groups compared.
The p value considered for statistical significance was
0.05. Data was stored and analyzed using SPSS® software
(IBM corp, Armonk, NY, version 20.0).
Results
We studied 615 acute HF patients (Fig. 1). Mean patient’s
age was 76 (±12) years, 278 (45.2%) patients were male,
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60.3% had left ventricular systolic dysfunction and 42.4%
(261 patients) had ejection fraction< 35%. The percentage
of patients with devices was modest, 7.3% of the patients
with severe dysfunction; however we were dealing with an
acute HF cohort of old and very old fragile patients.
Median (interquartile range) admission hsCRP was 20.3
(9.5–55.5) mg/L. In 256 (41.6%) patients, an infection was
considered as the factor precipitating or decompensating
HF [68.0% had a respiratory infection, 15.2% a urinary
infection, 7.8% a cutaneous infection, in 2.0% of the
patients there were other, rarer, foci of infection (abdom-
inal, cardiovascular, bones/joints), and in 7.0% the infec-
tious focus remained unknown]. Table 1 compares
patients according to infection status upon admission.
Table 1 Comparison between acute HF patients with and without an infectious condition underlying cardiac decompensation
Characteristics Non-infected patients (n = 359) Infected patients (n = 256) p-value
Male sex, n (%) 175 (48.7) 103 (40.2) 0.04
Age, mean (SD) 75 (12) 79 (11) < 0.001
Atrial fibrillation, n (%) 173 (48.2) 107 (41.8) 0.12
Diabetes mellitus, n (%) 159 (44.3) 94 (36.7) 0.06
Coronary heart disease, n (%) 159 (44.4) 92 (36.0) 0.04
Admission NYHA IV (vs II/III) 209 (58.2) 162 (63.3) 0.29
Admission heart rate (bpm), mean (SD) 90 (25) 88 (21) 0.34
Admission systolic blood pressure (mmHg), mean (SD) 136 (31) 130 (28) 0.01
Left ventricular systolic dysfunction, n (%) 234 (65.1) 137 (53.5) 0.003
Haemoglobin (mmol/L), mean (SD) 7.4 (1.4) 7.1 (1.3) 0.001
Leukocytes (cells/μL) 7934 (3056) 9704 (4122) < 0.001
Neutrophils (cells/μL) 5774 (2511) 7733 (3815) < 0.001
Monocyte-to-Lymphocyte Ratio, mean (SD) 0.54 (0.37) 0.65 (0.40) 0.001
Glomerular filtration rate (mL/min/1.73m2) 48.3 (20.9) 44.9 (20.7) 0.05
C-reactive protein (mg/L), median (IQR) 12.8 (7.1–24.2) 53.1 (22.8–116.0) < 0.001
C-reactive protein ≥25 mg/L 82 (22.8) 186 (72.7) < 0.001
BNP (pmol/L), median (IQR) 458.8 (257.2–783.5) 547.4 (293.7–858.1) 0.08
Acetylsalicylic acid, n (%) 174 (48.5) 119 (46.5) 0.65
Statin, n (%) 188 (52.4) 120 (46.9) 0.19
1-year death 130 (36.2) 102 (39.8) 0.36
BNP B-type natriuretic peptide, hsCRP high sensitivity C-reactive protein, IQR interquartile range, NYHA New York Heart Association, SD standard deviation
Fig. 1 Study flow chart and main results
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Apart an expected higher admission hsCRP (median value
53.1 mg/L in infected patients against 12.8 mg/L median
value in non-infected) and neutrophil count, patients with
a concomitant infection at admission were more often
older women, with higher proportion of patients with HF
with preserved ejection fraction and were more often
admitted with lower systolic blood pressure, lower haemo-
globin and worse renal function. Acute HF patients with a
concomitant infection less frequently had coronary artery
disease and there was also a non-significant trend for
them to have higher BNP levels and less often to have
diabetes.
The AUC for hsCRP in the prediction of infection as
the cause underlying cardiac decompensation was of
0.79 (0.76–0.83), p < 0.001. Figure 2 depicts the ROC
curve of the association of hsCRP with an infectious
condition. The hsCRP value of 25 mg/L corresponded to
the best cut-off for associated infection prediction. Using
the cut-off of 25 mg/L, infection would be detected with
a sensitivity of 72.7% and a specificity of 77.2%. The
positive predictive value for infection when hsCRP
≥25 mg/L was 69.4% and the negative predictive value
for infection when hsCRP< 25 mg/L was 79.9% (Fig. 1).
If the classically accepted cut-off of 10 mg/L used in the
general population and stable coronary heart disease was
to be applied in this study sample of acute HF patients,
the sensitivity would be of 91.4% and the specificity of
38.7%; this 10 mg/L cut-off would show a higher
negative predictive value of 86.3%, however the positive
predicted value would result unacceptably low – 51.5%.
Table 2 shows the comparison between patients admit-
ted with hsCRP< 25 mg/L and those with hsCRP≥25 mg/
L. Patients with higher admission hsCRP more often had
an infectious condition underlying acute HF, were more
often male, with lower admission systolic blood pressure,
lower admission haemoglobin, higher BNP, and expectedly
higher neutrophil count.
Despite the different distribution of variables accord-
ing to the coexistence of infection upon admission, the
only variables independently associated with an infec-
tious condition complicating acute HF were age, neutro-
phil count and hsCRP, both analysed as a continuous
and as a categorical variable (cut-off 25 mg/L). Table 3
shows the multivariate regression models for infection
prediction in acute HF, with hsCRP analysed as a con-
tinuous and as a categorical variable. Increasing age,
neutrophil count and admission hsCRP were independ-
ently associated with the coexistence of an infection
upon admission with acute HF. Patients admitted with
acute HF who presented with a hsCRP≥25 mg/L had an
approximately 8-fold higher risk of having an infection
as the cause of cardiac decompensation than when
admission hsCRP was lower.
Independent predictors of elevated hsCRP at admis-
sion (≥25 mg/L) were male gender (OR = 1.87, 95% CI:
1.20–2.91) and haemoglobin (OR = 0.76, 95% CI: 0.64–
0.90 per each mmol/L increase). An infectious condition
was also an independent predictor of elevated hsCRP
with a 8-fold higher risk. Adjustments were made
accounting for age, diabetes, coronary artery disease,
admission systolic blood pressure, admission glomerular
filtration rate, BNP, leukocyte and neutrophil counts,
monocyte to linfocyte ratio and left ventricular systolic
dysfunction (data not shown).
Discussion
Our results add some important findings to the current
knowledge on the role of hsCRP and inflammation in
acute HF. In our 615 patients’ cohort, 25 mg/L value
appears to be the best hsCRP cut-off for prediction of
concomitant infection in the acute HF setting. In 72.7%
of the patients presenting with acute HF, in whom an
underlying infection decompensates HF, the hsCRP
value was ≥25 mg/L. On the other hand, if a patient pre-
sented with acute HF and had an admission hsCRP
≥25 mg/L he had an almost 70% probability of having an
infectious condition causing the cardiac decompensa-
tion. Our results also suggest that patients hospital-
admitted with acute HF that have a hsCRP< 25 mg/L we
are almost 80% certain that no infection complicates the
clinical scenario.
In accordance with previous publications [18, 19, 23],
we report a high prevalence of concomitant infection in
patients presenting with acute HF and reinforce
Fig. 2 Receiver-operating characteristic (ROC) curve of the ability of
admission hsCRP for infection prediction in patients hospitalized
with acute HF. The AUC is of 0.79 (0.76–0.83), p < 0.001
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infection as an important precipitant of acute HF.
Procalcitonin, another inflammatory biomarker, was
found to be higher in patients with HF in comparison
with control subjects and patients in whom acute HF
and infection coexisted presented even higher levels of
procalcitonin [24]. The recognition that an often life
threatening infection precipitates acute HF and that the
diagnosis of superimposed infections is sometimes diffi-
cult in this context has led to the development of strat-
egies to more accurately identify coexistent infection.
Procalcitonin has emerged as a promising tool for the
early and accurate diagnosis of pneumonia and for guid-
ing antibiotic therapy in acute HF patients [25, 26].
However, hsCRP is an inflammatory marker more widely
available, more extensively studied, and much more
familiar to physicians treating HF patients. Moreover,
the AUC reported for procalcitonin in the diagnosis of
pneumonia was of 0.72, which is lower than the one we
report for the association of hsCRP with an infection
underlying HF decompensation – AUC = 0.79 [27].
HsCRP has additional recognized prognostic informa-
tion in the HF context rendering it a perhaps more use-
ful biomarker in acute HF [17, 28–30].
Despite the differences between groups of patients
with hsCRP below and above the 25 mg/L cut-off, the
only variables independently associated with higher
hsCRP were male gender, lower hemoglobin and con-
comitant infection. The relationship between gender and
hsCRP is still controversial; however, inflammatory acti-
vation and the role of inflammation are clearly gender
influenced. Depending on the population studied higher
hsCRP values either in male or in female have been
reported [31, 32]. Anemia is a common comorbidity in
inflammatory conditions – anemia of chronic diseases
[33]. Despite differences between groups of acute HF
patients with and without a concomitant infection upon
admission, the only independent predictors of infection
were older age, higher neutrophil count and higher
hsCRP. Older patients become progressively immune
incompetent in one hand and have higher comorbidity
burden in the other hand and, therefore, are more prone
to infectious complications of their chronic diseases
[34]. HsCRP is a well studied and accepted non-specific
biomarker of inflammatory and infectious conditions
[35]. Of note that the monocyte-to-lymphocyte ratio was
not independently associated with the coexistence of an
infectious condition; this eventually reflects the fact that
the monocyte-to-lymphocyte ratio is probably more
associated with chronic inflammatory burden and car-
diovascular risk [36, 37] and less a mirror of acute
changes in response to infection.
As a low-grade inflammatory disorder we would
expect patients with HF, and particularly those with
acute HF, to present with elevated hsCRP. In fact, in our
patient population, those with acute HF and no infec-
tious condition had a median hsCRP value at admission
Table 2 Comparison between acute HF patients admitted with hsCRP below and above 25 mg/L
Characteristics hsCRP< 25 mg/L (n = 347) hsCRP≥25 mg/L (n = 268) p-value
Male sex, n (%) 144 (41.5) 134 (50.0) 0.04
Age, mean (SD) 76 (12) 77 (12) 0.53
Atrial fibrillation, n (%) 159 (45.8) 121 (45.1) 0.88
Diabetes mellitus, n (%) 149 (42.9) 104 (38.8) 0.30
Coronary heart disease, n (%) 143 (41.2) 108 (40.3) 0.83
Admission NYHA IV (vs II/III) 207 (59.6) 164 (61.2) 0.87
Admission heart rate (bpm), mean (SD) 88 (24) 89 (23) 0.58
Admission systolic blood pressure (mmHg), mean (SD) 137 (29) 130 (29) 0.01
Left ventricular systolic dysfunction, n (%) 215 (62.0) 156 (58.2) 0.22
Haemoglobin (mmol/L), mean (SD) 7.4 (1.3) 7.1 (1.3) < 0.001
Leukocytes (cells/μL) 7918 (3172) 9645 (3972) < 0.001
Neutrophils (cells/μL) 5861 (2830) 7534 (3543) < 0.001
Monocyte-to-Lymphocyte Ratio, mean (SD) 0.53 (0.36) 0.67 (0.40) < 0.001
Glomerular filtration rate (mL/min/1.73m2) 48.0 (20.7) 45.4 (21.0) 0.13
Infectious condition at admission, n (%) 70 (20.2) 186 (69.4) < 0.001
BNP (pmol/L), median (IQR) 446.8 (252.2–797.0) 549.0 (304.4–848.8) 0.05
Acetylsalicylic acid, n (%) 167 (48.1) 126 (47.0) 0.69
Statin, n (%) 165 (47.6) 143 (53.4) 0.19
1-year death 130 (37.5) 102 (38.1) 0.88
BNP B-type natriuretic peptide, hsCRP high sensitivity C-reactive protein, IQR interquartile range, NYHA New York Heart Association, SD standard deviation
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of 12.8 mg/L. It is important to remember that inflam-
matory and oxidative acute and chronic conditions may
affect the electrophysiological functions, and the elec-
trical/anatomical properties of cardiac function [38].
This could have been addressed by device interrogation;
however, the number of patients with devices was low.
This issue is even more pertinent if we consider this is a
cohort of old HF patients and that 41.1% of them were
diabetic, factors known to affect patients’ response to
device implantation and HF prognosis [39, 40].
The prognostic significance of hsCRP is documented
in HF, mainly in the chronic context [9, 13, 41]; but also
in the acute setting [29]. The interpretation of hsCRP in
acute HF patients may be more intricate precisely
because infectious intercurrences frequently underlie the
HF worsening and hsCRP in a non-specific marker of
inflammation. Part of the acute HF treatment implies ad-
dressing the decompensating factor and a clear recogni-
tion of an infection and its treatment may be crucial [42].
This is even more important if we consider that clinical
manifestations of infection can be very mild and atypical
in this group of classically old and very old patients.
Previous studies have shown that hsCRP has a prog-
nostic role in acute HF patients and that higher levels of
this acute-phase protein are associated with higher mor-
tality [29]. Most studies that demonstrated an inflamma-
tory response in acute HF excluded patients with
concurrent infection or other inflammatory conditions
in order to prove the independent role of inflammation
in HF [10, 17]. The exact value that could help
Table 3 Predictors of an infectious condition underlying decompensated HF: multivariate models
OR (95% CI) P-value Wald
Age, per year 1.03 (1.01–1.05) 0.01 6.60
hsCRP≥25 mg/L 8.05 (5.24–12.36) < 0.001 90.82
Male sex 0.68 (0.43–1.08) 0.10 2.72
Diabetes mellitus 0.89 (0.72–1.10) 0.27 1.22
Coronary heart disease 0.73 (0.47–1.12) 0.15 2.05
Admission systolic blood pressure,
per mmHg
1.00 (0.99–1.00) 0.18 1.77
Haemoglobin, per mmol/L 0.87 (0.74–1.03) 0.11 2.53
BNP per 100 pmol/L 1.02 (0.98–1.06) 0.30 1.09
Leukocytes per 1000 cells/μL 0.90 (0.76–1.06) 0.21 1.58
Neutrophils per 1000 cells/μL 1.32 (1.09–1.60) 0.005 7.88
Monocyte-to-Lymphocyte Ratio 0.96 (0.53–1.74) 0.88 0.02
Glomerular filtration rate per 10
mL/min/1.73 m2
1.08 (0.96–1.21) 0.22 1.48
Left ventricular systolic dysfunction 0.76 (0.48–1.22) 0.26 1.28
OR (95% CI) P-value
Age, per year 1.02 (1.00–1.04) 0.02 5.51
hsCRP per 1 mg/L 1.02 (1.01–1.02) < 0.001 44.85
Male sex 0.84 (0.54–1.30) 0.44 0.60
Diabetes mellitus 0.90 (0.73–1.10) 0.31 1.02
Coronary heart disease 0.77 (0.51–1.17) 0.23 1.46
Admission systolic blood pressure,
per mmHg
0.99 (0.99–1.00) 0.11 2.51
Haemoglobin, per mmol/L 0.86 (0.73–1.02) 0.08 3.17
BNP per 100 pmol/L 1.01 (0.98–1.05) 0.48 0.50
Leuckoytes per 1000 cells/μL 0.88 (0.72–1.08) 0.22 1.51
Neutrophils per 1000 cells/μL 1.33 (1.06–1.66) 0.01 6.31
Monocyte-to-Lymphocyte Ratio 0.84 (0.45–1.55) 0.57 0.32
Glomerular filtration rate per 10
mL/min/1.73m2
1.05 (0.94–1.17) 0.41 0.67
Left ventricular systolic dysfunction 0.77 (0.49–1.20) 0.25 1.34
BNP B-type natriuretic peptide, CI Confidence Interval, hsCRP high sensitivity C-reactive protein, OR Odds Ratio
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distinguishing patients with elevated hsCRP in relation
with the inflammatory process underlying HF and those
with elevated hsCRP due to a concomitant infectious
process was never studied in HF. This is important, par-
ticularly in acute HF, not only to help defining the treat-
ment strategy but also for clinicians to be able to
interpret the prognostic value of hsCRP.
To the best of our knowledge this is the first study
proposing a cut-off value beyond which an infection is
highly prevalent in acute HF patients and therefore
needs to be sought. The existence of such a cut-off can
eventually help clinicians treating acute HF patients in
their everyday clinical practice, representing a major
advantage in the management of these patients with
unquestionable clinical implications.
We propose the cut-off of 25 mg/L as the one beyond
which hsCRP elevation should be considered as not
totally attributable to low grade inflammation in acute
HF. This value is higher than the arbitrary value of
10 mg/L accepted for the general population and
patients with stable coronary artery disease.
This 25 mg/L cut-off value for hsCRP that we propose
is grown out of a relatively large population of “real
world” acute HF patients. The fact that it is significantly
higher than the one for the general population is not
totally unexpected since acute HF patients are experien-
cing a decompensation/exacerbation of an inflammatory
condition. The use of the classical cut-off of 10 mg/L
would have an elevated sensitivity (over 90%), but an
also extremely elevated false positive rate of 61.3% and a
low positive predictive value with only approximately
half of the patients having an infectious condition when
hsCRP value at acute HF presentation was ≥10 mg/L.
Our study has some limitations that need to be noted.
The single center nature of the study implies generalis-
ability concerns. The retrospective nature of the study
has known inherent problems, namely concerning the
availability and quality of the data collected. A treatment
and general approach bias related to the fact that physi-
cians treating HF patients were aware of the ongoing
registry should also be kept in mind. It would have also
been interesting to have included in the multivariate
models other inflammatory markers, such as cytokines
or TNF-α, however, no such data were available. Perhaps
the most important setback comes from the definition of
infection. We relied on the clinical evaluation of the
attending physician and its registry in the discharge
diagnosis list or in the discharge record. Criteria could
be different between the physicians but, consulting the
discharge notes, there were clinical and laboratory or
radiologic criteria to support the diagnosis of infection.
Apart these limitations we were able to show that in
the setting of acute HF, clinicians can rely on hsCRP
values to adequately diagnose infection as the trigger of
the decompensation and to treat it in accordance. Acute
HF patients represent a group with a low grade inflam-
matory condition experiencing an episode of decompen-
sation and an elevation of hsCRP is already expected.
We have documented such hsCRP elevation in non-
infected patients as well as an even higher elevation in
infected ones. We have as well documented the ability of
hsCRP to predict a concurrent infectious condition in
acute HF decompensations.
Conclusions
In patients with acute HF presenting with a
hsCRP≥25 mg/L, an infectious condition complicating
or underlying cardiac decompensation should be sought.
Almost 80% of the patients with hsCRP< 25 mg/L are
not infected and 69.4% of those with higher hsCRP have
a concomitant infection.
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